Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Robson

Showing results (121-130 of 218) with videos related to

Pageof 22
Sort By:
Human and Ecological Risk Assessment : HERA|July 22, 2021
Pesticide use in Thailand: Current situation, health risks, and gaps in research and policyWisanti Laohaudomchok, Noppanun Nankongnab, Somkiat Siriruttanapruk, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 29, 2011
NCCN molecular testing white paper: effectiveness, efficiency, and reimbursementPaul F Engstrom, Mara G Bloom, George Daniel Demetri, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 20, 2009
The 6q22.33 locus and breast cancer susceptibilityTomas Kirchhoff, Zhang-qun Chen, Bert Gold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary reportNicolas Girard, Emil Lou, Christopher G Azzoli, et al.
Breast Cancer Research and Treatment|May 17, 2008
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an updateOphira Ginsburg, Parviz Ghadirian, Jan Lubinski, et al.
Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.
Clinical Breast Cancer|October 28, 2008
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasibleChau Dang, Gabriella D'Andrea, Diana Lake, et al.
JCO Precision Oncology|July 29, 2021
Comprehensive Breast Cancer Risk Assessment for <i>CHEK2</i> and <i>ATM</i> Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick ModelShannon Gallagher, Elisha Hughes, Allison W Kurian, et al.
Gynecologic Oncology|March 13, 2021
Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriersRenee Cowan, Silvana Pedra Nobre, Nisha Pradhan, et al.
Breast Cancer Research and Treatment|February 6, 2013
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?Steven A Narod, Kelly Metcalfe, Henry T Lynch, et al.
Pageof 22

Showing results (121-130 of 218) with videos related to

Sort By:
Pageof 22
Human and Ecological Risk Assessment : HERA|July 22, 2021
Pesticide use in Thailand: Current situation, health risks, and gaps in research and policyWisanti Laohaudomchok, Noppanun Nankongnab, Somkiat Siriruttanapruk, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 29, 2011
NCCN molecular testing white paper: effectiveness, efficiency, and reimbursementPaul F Engstrom, Mara G Bloom, George Daniel Demetri, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 20, 2009
The 6q22.33 locus and breast cancer susceptibilityTomas Kirchhoff, Zhang-qun Chen, Bert Gold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary reportNicolas Girard, Emil Lou, Christopher G Azzoli, et al.
Breast Cancer Research and Treatment|May 17, 2008
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an updateOphira Ginsburg, Parviz Ghadirian, Jan Lubinski, et al.
Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.
Clinical Breast Cancer|October 28, 2008
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasibleChau Dang, Gabriella D'Andrea, Diana Lake, et al.
JCO Precision Oncology|July 29, 2021
Comprehensive Breast Cancer Risk Assessment for <i>CHEK2</i> and <i>ATM</i> Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick ModelShannon Gallagher, Elisha Hughes, Allison W Kurian, et al.
Gynecologic Oncology|March 13, 2021
Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriersRenee Cowan, Silvana Pedra Nobre, Nisha Pradhan, et al.
Breast Cancer Research and Treatment|February 6, 2013
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?Steven A Narod, Kelly Metcalfe, Henry T Lynch, et al.
Pageof 22